Tumoral expression of PD-L1 or PD-L1 plus tumor-infiltrating CD8+ T cell counts predicted shorter PFS and OS for patients treated with sunitinib or pazopanib in a TMA of mRCC cases [10]. Here, CD274 is linked to neoplasm.